Furthermore, Matlung et al. [107] found that both anti-tumor antibody and IgG-FcγR-dependent cancer killing activity by PMN could be augmented by trogocytosis and CD47-SIRPα checkpoint inhibitors. This evidence concerns the gene SIRPA and cancer.